0001662579-23-000095.txt : 20230919
0001662579-23-000095.hdr.sgml : 20230919
20230919192009
ACCESSION NUMBER: 0001662579-23-000095
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 2
CONFORMED PERIOD OF REPORT: 20230918
FILED AS OF DATE: 20230919
DATE AS OF CHANGE: 20230919
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Adams Kendra
CENTRAL INDEX KEY: 0001991929
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39567
FILM NUMBER: 231265059
MAIL ADDRESS:
STREET 1: C4 THERAPEUTICS, INC.
STREET 2: 490 ARSENAL WAY, SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: C4 Therapeutics, Inc.
CENTRAL INDEX KEY: 0001662579
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 475617627
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
BUSINESS PHONE: (617) 231-0700
MAIL ADDRESS:
STREET 1: 490 ARSENAL WAY
STREET 2: SUITE 120
CITY: WATERTOWN
STATE: MA
ZIP: 02472
3
1
wk-form3_1695165599.xml
FORM 3
X0206
3
2023-09-18
0
0001662579
C4 Therapeutics, Inc.
CCCC
0001991929
Adams Kendra
C/O C4 THERAPEUTICS, INC.
490 ARSENAL WAY #120
WATERTOWN
MA
02472
0
1
0
0
Chief Financial Officer
Common Stock
21640
D
Stock Option (Right to Buy)
19
2030-11-08
Common Stock
57375
D
Stock Option (Right to Buy)
22.71
2032-02-13
Common Stock
45000
D
Stock Option (Right to Buy)
5.67
2033-02-12
Common Stock
75000
D
Performance Restricted Stock Units
2025-02-28
Common Stock
16500
D
Includes a grant of 15,000 restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. The RSUs vest in four equal annual installments, with the first installment vesting on February 13, 2024, subject to the Reporting Person's continued service on each vesting date.
Represents underlying unexercised stock options that were granted on November 9, 2020. The terms of the original grant provide that 25% of this option vested and became exercisable on November 9, 2021, with the remainder vesting in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service on each vesting date.
This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 14, 2022, subject to the Reporting Person's continued service on each vesting date.
This option vests and becomes exercisable in sixteen equal quarterly installments, with the first installment vested on May 13, 2023, subject to the Reporting Person's continued service on each vesting date.
Each performance restricted stock unit ("PRSU") represents the contingent right to receive one share of the Issuer's Common Stock upon vesting and settlement. 4,500 PRSUs shall vest upon satisfaction of three escalating share price vesting milestones, and the remaining PRSUs vest upon satisfaction of certain discovery and clinical milestones.
Exhibit 24 - Power of Attorney
/s/ Jolie M. Siegel, Attorney-in-Fact
2023-09-19
EX-24
2
adams.txt
EX-24
POWER OF ATTORNEY
Know all by these presents, that the undersigned hereby constitutes and
appoints each of Jolie M. Siegel, Shagha T. Russell, Andrew J. Hirsch, Shoaib
Ghias and Nathan Needle, signing singly, the undersigned's true and lawful
attorney-in-fact to:
(1) execute for and on behalf of the undersigned, in the undersigned's
capacity as an officer and/or director of C4 Therapeutics, Inc. (the
"Company"), (i) Form ID, including any attached documents, to effect
the assignment of codes to the undersigned to be used in the
transmission of information to the United States Securities and
Exchange Commission using the EDGAR System, (ii) Forms 3, 4 and 5,
(iii) Schedule 13D, (iv) Schedule 13G and (v) amendments of each
thereof, in accordance with Section 16(a) of the Securities Exchange
Act of 1934, as amended, and the rules thereunder;
(2) do and perform any and all acts for and on behalf of the undersigned
which may be necessary or desirable to complete and execute any such
Form 3, 4 or 5, Schedule 13D, Schedule 13G or any amendments thereto
and timely file such form with the United States Securities and
Exchange Commission and any stock exchange or similar authority; and
(3) take any other action of any type whatsoever in connection with the
foregoing which, in the opinion of such attorney-in-fact, may be of
benefit to, in the best interest of, or legally required by, the
undersigned, it being understood that the documents executed by such
attorney-in-fact on behalf of the undersigned pursuant to this Power
of Attorney shall be in such form and shall contain such terms and
conditions as such attorney-in-fact may approve in such attorney-in-
fact's discretion.
The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this Power of Attorney and the
rights and powers herein granted. The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming, nor is the Company assuming, any of the
undersigned's responsibilities to comply with Section 16 or Regulation 13D-G of
the Securities Exchange Act of 1934, as amended. The undersigned hereby agrees
to indemnify the attorney-in-fact and the Company from and against any demand,
damage, loss, cost or expense arising from any false or misleading information
provided by the undersigned to the attorney-in-fact.
This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact. This Power of Attorney may be filed with the United
States Securities and Exchange Commission as a confirming statement of the
authority granted herein. This Power of Attorney supersedes any prior power of
attorney in connection with the undersigned's capacity as an officer and/or
director of the Company. This Power of Attorney shall expire as to any
individual attorney-in-fact if such attorney-in-fact ceases to be an executive
officer of the Company.
IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of September 18, 2023.
/s/ Kendra Adams
---------------------------------
Name: Kendra Adams